We are live on ! Find out more
STAB

Statera Biopharma, Inc. Common Stock

Delisted

STAB was delisted on the 11th of January, 2023.

19 hedge funds and large institutions have $715K invested in Statera Biopharma, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

6% more funds holding

Funds holding: 1819 (+1)

2% more capital invested

Capital invested by funds: $699K → $715K (+$15.8K)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
19
Holders Change
+1
Holders Change %
+5.56%
% of All Funds
0.53%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
3
Reduced
4
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$385K +$22K +5,400 +6%
LTFS
2
Ladenburg Thalmann Financial Services
Florida
$158K +$81.5K +20,045 +106%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$51K +$48.6K +11,937 New
VKH
4
Virtu KCG Holdings
New York
$48K -$47.3K -11,618 -51%
Morgan Stanley
5
Morgan Stanley
New York
$45K -$17.6K -4,330 -29%
BA
6
BlackRock Advisors
Delaware
$12K
TDC
7
Thompson Davis & Co
Virginia
$8K +$7.32K +1,800 New
WA
8
Winfield Associates
Ohio
$3K
Wells Fargo
9
Wells Fargo
California
$3K +$1.73K +425 +184%
Bank of America
10
Bank of America
North Carolina
$1K -$65 -16 -10%
Group One Trading
11
Group One Trading
Illinois
$1K +$464 +114 New
Renaissance Technologies
12
Renaissance Technologies
New York
-$71K -16,266 Closed
UBS Group
13
UBS Group
Switzerland
-$24.9K -6,124 -97%
Citigroup
14
Citigroup
New York
-$7K -1,611 Closed

STAB Hedge Fund Activity: Q3 2015 in Review

19 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q3 2015, worth a combined $715K — up 2.3% from $699K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new STAB positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Ladenburg Thalmann Financial Services, adding an estimated $81.5K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $71K sold.

  • 19 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q3 2015, up from 18 in Q2 2015.
  • Funds reported $715K of Statera Biopharma, Inc. Common Stock stock for Q3 2015, up 2.3% quarter-over-quarter.
  • 3 funds opened new Statera Biopharma, Inc. Common Stock positions in Q3 2015 and 2 closed out, a net change of +1 holder.
  • The largest Statera Biopharma, Inc. Common Stock buyer in Q3 2015 was Ladenburg Thalmann Financial Services, an estimated $81.5K added.
  • The largest Statera Biopharma, Inc. Common Stock seller in Q3 2015 was Renaissance Technologies, an estimated $71K sold.

Based on aggregated 13F filings for Q3 2015.